Heart Failure Drugs Market to Record Growth of USD 2.69 Billion from 2020 to 2025 | Technavio

Key Considerations for Market Forecast:

  • Impact of lockdowns, supply chain disruptions, demand destruction and changing customer behavior
  • Optimistic, probable and pessimistic scenarios for all markets as the impact of the pandemic unfolds
  • Market estimates before and after COVID-19
  • Quarterly impact analysis and updates on market estimates

Get innovative insights on the Heart Failure Drugs Market here!

Analysis of the main players in the market
The heart failure drugs market is fragmented and the vendors are deploying organic and inorganic growth strategies to compete in the market. The global market for heart failure drugs is fragmented in nature as numerous generic drug manufacturers and pharmaceutical giants provide drugs for one disease. Companies are focused on gaining competitive advantage by realizing new technologies and increasing their margins in response to changing market conditions in end-use industries. Additionally, vendors compete on the basis of factors such as operating costs, innovation, price, and product quality. Some of the factors that are likely to make the market more competitive are the prices of raw materials and finished products, increasing rate of product demand, capacity expansion plans, and supply flow.

Some dominant players and their product offerings

Amgen Inc.
The company operates in a single line of business and offers human therapeutics. The company offers drugs for heart failure, namely Omecamtiv Mecarbil.

Astra Zeneca Plc
The company generates revenue by developing and manufacturing pharmaceutical products. The company offers drugs for heart failure, namely Farxiga.

Bayer AG
The company operates in key business segments, including pharmaceuticals, crop science and consumer health. The company offers drugs for heart failure, namely Verquvo. Additionally, the segment focuses on the development, production and marketing of prescription products in the fields of oncology, ophthalmology, hematology, contrast agents and diagnostic imaging equipment.

Get more information about vendors and their product offerings as you go. Download our sample report FREE!

Heart Failure Drugs Market 2021-2025: Segmentation Analysis

  • Drug class
    • Beta-blockers
    • ARB
    • ACE inhibitors
    • Others

The growth of the heart failure drugs market share by the beta blockers segment will be significant during the forecast period. The beta-blockers segment will continue to account for the largest market share during the forecast period, according to this market outlook report from Technavio

  • Geography
    • North America
    • Europe
    • Asia
    • LINE

North America has emerged as the largest regional segment of the market. The market is growing in this region mainly due to the high incidence of cardiovascular disease in the United States, which is driving the rising consumption of cardiovascular disease drugs. 38% of market growth will come from North America during the forecast period. The United States and Canada are the major heart failure drug markets in North America. Huge investments in the pharmaceutical industry, the presence of pharmaceutical giants in the region and the high prevalence rate of heart failure cases, along with the huge economic burden associated with it are some of the major factors supporting the dominance of the United States in the region and even globally. The rising prevalence rate of heart failure cases coupled with increasing R&D efforts and recent product launches in the region is expected to boost the demand for heart failure drugs in the region.

To customize this report to get additional information about each contributing segment, Talk to our analyst

Heart Failure Drugs Market 2021-2025: Drivers and Challenges
The heart failure drugs market is driven by the increase in the geriatric population, an increase in chronic diseases and an increasing sedentary lifestyle. A sedentary lifestyle for several years is directly associated with increased risk of cardiovascular disease, type 2 diabetes and premature mortality. Chronic diseases such as diabetes, high blood pressure, and obesity are some of the potential factors for heart failure. There has been a continued rise in chronic diseases, such as diabetes, which has caused serious concern among medical professionals around the world. These diseases are likely to lead to increased demand for heart failure drugs over the forecast period.

A highly generic market is one of the major factors hampering the growth of the heart failure drugs market. The global market for heart failure drugs is highly generic, which means that generic versions of drugs have captured a huge portion of the market. Generic substitution (GS) has been successful in increasing generic drug penetration and reducing overall pharmaceutical spending by patients. However, this has increased price competition in the industry and reduced the overall revenue generated by leading companies in the branded drug market.

Get insights into the drivers and challenges that are likely to impact the market by Download our FREE sample report

Market factors
Market challenges
Market trends
Supplier Landscape

  • Suppliers Covered
  • Ranking of suppliers
  • Positioning on the supplier market
  • Competitive scenario

Reports you may be interested in:

Stroke Therapy Market by Type and Geography – Forecast and Analysis 2021-2025

Generic Drugs Market by Type and Geography – Forecast and Analysis 2021-2025

Heart Failure Drugs Market Scope

Report cover


Page number


base year


Forecast period


Growth momentum and CAGR

Accelerate at a CAGR of 7.75%

Market Growth 2021-2025

$2.69 billion

Market structure


Annual growth (%)


Regional analysis

North America, Europe, Asia and ROW

Successful market contribution

North America at 38%

Main consumer countries

United States, Canada, Germany, United Kingdom and China

Competitive landscape

Leading companies, competitive strategies, scope of consumer engagement

Profiled companies

Amgen Inc., AstraZeneca Plc, Bayer AG, Bristol-Myers Squibb Co., Daiichi Sankyo Co. Ltd., Eli Lilly and Co., Exelixis Inc., Gilead Sciences Inc., Novartis AG and Pfizer Inc.

Market dynamics

Parent Market Analysis, Market Growth Drivers and Barriers, Fast and Slow Growing Segment Analysis, Impact of COVID-19 and Future Consumer Dynamics, Market Condition Analysis for the Forecast Period,

Personalization area

If our report does not include the data you are looking for, you can contact our analysts and customize the segments.

About Us
Technavio is a global leader in technology research and consulting. Their research and analysis focuses on emerging market trends and provides actionable insights to help companies identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialist analysts, Technavio’s reporting library consists of over 17,000 reports and counts, spanning 800 technologies, spanning 50 countries. Their customer base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing customer base relies on Technavio’s comprehensive coverage, in-depth research, and actionable market intelligence to identify opportunities in existing markets and potentials and assess their competitive positions in changing market scenarios.

Technavio Research
Jesse Maida
Media & Marketing Manager
USA: +1 844 364 1100
UK: +44 203 893 3200
E-mail: [email protected]
Website: www.technavio.com/


Comments are closed.